On April 6, Zeng Shaogui, Chairman of Hybio Pharmaceutical, and Yu Pinxiang, Executive President of Hybio Pharmaceutical Inc. led a team to visit Shenzhen Bay Laboratory and had an in-depth exchange of views on basic research, transformation of research findings and cooperation plans in the polypeptide industry, and reached consensus on the establishment of the “Joint Innovation Center for the Industrialization of Innovative Polypeptide Drugs”. Wu Yun-Dong, the Executive Vice Director of the Laboratory, and Tu Huan, the Vice Director, attended the panel discussion.
Tang Yangming, Vice President and Board Secretary of Hybio Pharmaceutical, Yang Di, Vice President and Board Secretary of Hybio Pharmaceutical, Zhou Yaoqi, Vice Director of Institute of Systems and Physical Biology of Shenzhen Bay Laboratory, Li Zigang, Executive Director of Pingshan Translational Medicine Center of Shenzhen Bay Laboratory participated in the meeting.
Zeng Shaogui and his delegation visited the Shenzhen Bay Laboratory exhibition hall and equipment platform and learned in detail about the research direction of the laboratory, the transformation of findings and the construction of the research team.
At the panel discussion, Wu Yun-Dong expressed his hope that the two sides would carry out in-depth cooperation in scientific research projects, talent training and collaborative innovation between industry, academia and research through closer communication, especially giving full play to the Laboratory's advantages in translational research, practically speeding up the industrialization of research findings and helping the development of medical biology in Shenzhen. Zeng Shaogui said he was looking forward to strengthening exchanges and cooperation with Shenzhen Bay Laboratory in more areas and at a deeper level to promote the industrial transformation of innovative drugs in the polypeptide industry and achieve win-win cooperation. During the discussion, representatives from both sides had in-depth discussions on the research direction and transformation of polypeptide industry, and reached consensus on various cooperation plans such as peptide drug development and establishment of joint innovation research center. The two sides would further accelerate and deepen exchanges and cooperation, innovate cooperation models and jointly promote the innovative development of the biomedical industry in Shenzhen.
Hybio Group
Founded in 1998, with registered capitalRMB 400 million, headquarter located in Shenzhen High-Tech Park, Hybio is a leading peptides company in China specializing in the development, manufacture and commercialization of therapeutic peptides API and peptide-based drugs. With over 20 years’ experience, Hybio offers a full range of synthetic peptide products and services, as well as CRO and CDMO for research, clinical development and commercial application for pharmaceutical companies worldwide. The main products have been applied to treat the digestive diseases, cardio-cerebro-vascular diseases, diabetes, infectious disease, cancer, and senile diseases, etc. In 2011, Hybio was listed on Shenzhen Stock Exchange Market (stock code 300199), and became the first listed enterprise of manufacturing peptide drugs in China.
